Emblem Corp (EMC.V) moved to enter the conversation with its customers and put its finger on the pulse of strain efficacy when Strainprint™ Technologies, a Toronto-based analytical software developer, announced today that it had launched a co-branded version of its mobile app for Emblem.
According to the news release, the mobile outcomes-tracking app will allow Emblem to better understand customers needs and desires as well as providing patients a platform to track strain efficacy per symptom.
The resulting patient data can be parsed to run up to five independently reportable clinical studies.
If you’re concerned about your details getting pilfered, Strainprint™ Technologies was quick to point out that all versions of its software comply with HIPAA, PIPEDA and PHIPA privacy laws and all patient data will be treated as confidential.
Canabo Medical (CMM.V) is heading down a similar road in regard to data collection which speaks to the dearth of reliable studies on marijuana and its health-related benefits.
Strainprint is available to download for free on Google Play and Apple Store. However, Emblem patients will receive a unique code which will activate additional premium features such as redeemable discounts on Emblem products.
Okay, I gotta say it…
I still have a problem with the anecdotal aspect of marijuana studies. After all, anecdotal evidence has ‘proven’ vaccinations cause autism, resulting in 9,028 preventable deaths from June 3, 2007 to July 18, 2015, according to the website, jennymaccarthybodycount.com.
I know, people aren’t going to die if a patient misses the mark on rating the efficacy of Purple People Eater in treating migraines, but how accurate can these studies be? Especially since marijuana affects everyone differently.
Don’t get me wrong, this is a huge step in legitimizing marijuana in the eyes of the medical community, but mainstream GPs won’t jump on the MMJ treatment bandwagon until pot rolls out of a lab in pill form.
What this does mean?
What Emblem intends to build, and what Canabo has, will most likely form the backbone for modern clinical studies on the health benefits and therapeutic properties of cannabis. So, the data collected through Strainprint™, although subjective, will still have significance and could add some serious shareholder value if leveraged correctly.
FULL DISCLOSURE: Emblem Corp and Canabo Medical are EQUITY.GURU clients.
Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Gaalen Engen (see all)
- There’s no place like home: 3D Sustainable Developments prints an answer to the global housing crisis - February 10, 2020
- Germany’s corporate codetermination – cunningly co-committed or cataclysmically codependent? - February 3, 2020
- Pepsi, Nestle and Amazon: asymmetric risk and monopoly control - January 10, 2020